Chicago Capital LLC Has $47.53 Million Stock Position in Zoetis Inc. (NYSE:ZTS)

Chicago Capital LLC grew its holdings in Zoetis Inc. (NYSE:ZTS) by 0.3% during the 2nd quarter, HoldingsChannel reports. The firm owned 274,140 shares of the company’s stock after purchasing an additional 949 shares during the quarter. Zoetis comprises approximately 1.4% of Chicago Capital LLC’s holdings, making the stock its 29th largest position. Chicago Capital LLC’s holdings in Zoetis were worth $47,525,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also modified their holdings of the business. Webster Bank N. A. lifted its holdings in shares of Zoetis by 89.1% in the first quarter. Webster Bank N. A. now owns 174 shares of the company’s stock worth $29,000 after acquiring an additional 82 shares during the last quarter. Private Wealth Management Group LLC acquired a new stake in Zoetis in the fourth quarter valued at approximately $33,000. Neo Ivy Capital Management bought a new stake in shares of Zoetis during the fourth quarter worth $40,000. LRI Investments LLC bought a new stake in shares of Zoetis during the first quarter worth $43,000. Finally, Blue Bell Private Wealth Management LLC increased its holdings in shares of Zoetis by 111.6% during the first quarter. Blue Bell Private Wealth Management LLC now owns 273 shares of the company’s stock worth $46,000 after buying an additional 144 shares in the last quarter. 92.80% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

ZTS has been the topic of several recent research reports. Stifel Nicolaus reissued a “buy” rating and set a $200.00 price objective on shares of Zoetis in a report on Tuesday, August 27th. Piper Sandler lifted their price target on Zoetis from $195.00 to $210.00 and gave the company an “overweight” rating in a research note on Wednesday, August 14th. Argus raised Zoetis to a “strong-buy” rating in a research note on Friday, August 9th. Finally, BTIG Research lifted their target price on shares of Zoetis from $220.00 to $225.00 and gave the stock a “buy” rating in a research report on Monday, August 12th. Nine investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $217.11.

Zoetis Stock Up 1.4 %

ZTS stock traded up $2.64 during trading on Friday, reaching $189.23. 2,710,102 shares of the stock were exchanged, compared to its average volume of 2,661,613. The company has a current ratio of 3.45, a quick ratio of 2.09 and a debt-to-equity ratio of 1.32. Zoetis Inc. has a twelve month low of $144.80 and a twelve month high of $201.92. The firm’s 50 day moving average is $181.22 and its 200 day moving average is $174.57. The firm has a market cap of $85.73 billion, a P/E ratio of 36.45, a price-to-earnings-growth ratio of 2.87 and a beta of 0.88.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Tuesday, August 6th. The company reported $1.56 EPS for the quarter, beating analysts’ consensus estimates of $1.49 by $0.07. Zoetis had a net margin of 26.29% and a return on equity of 50.67%. The business had revenue of $2.36 billion during the quarter, compared to analyst estimates of $2.31 billion. During the same quarter in the previous year, the business posted $1.41 EPS. Zoetis’s quarterly revenue was up 8.3% on a year-over-year basis. As a group, research analysts forecast that Zoetis Inc. will post 5.84 EPS for the current year.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.